VIVUS Inc. (VVUS)
-NasdaqGS 13.16 
0.18(1.39%) 4:00PM EDT|After Hours
:
13.07 0.09 (0.68%) 5:57PM EDT
| Prev Close: | 12.98 |
|---|
| Open: | 13.06 |
|---|
| Bid: | 11.98 x 100 |
|---|
| Ask: | 13.14 x 1100 |
|---|
| 1y Target Est: | 17.68 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 12.80 - 13.40 |
|---|
| 52wk Range: | 9.86 - 31.21 |
|---|
| Volume: | 1,857,259 |
|---|
| Avg Vol (3m): | 2,478,770 |
|---|
| Market Cap: | 1.32B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation oEDGAR Online(Tue 9:06AM EDT)
- The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Doesat Seeking Alpha(Tue 6:56AM EDT)
- The 9 Most Obese Countries in the Worldat Motley Fool(Mon, May 20)
- Vivus Taps Into More Cashat Seeking Alpha(Sun, May 19)
- 25 Belt-Busting Obesity Factsat Motley Fool(Sat, May 18)
- VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial StatemeEDGAR Online(Thu, May 16)
- VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior NotesGlobeNewswire(Thu, May 16)
- Weight Loss Isn't Just for Looking Good Anymoreat Motley Fool(Wed, May 15)
- Is Vivus a Buy at These Prices?at Wall St. Cheat Sheet(Wed, May 15)
- VIVUS INC FinancialsEDGAR Online Financials(Wed, May 15)
- Vivus to sell $200 million in convertible debtAP(Wed, May 15)
- Vivus - Mild Drama Continuesat Seeking Alpha(Wed, May 15)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, May 15)
- VIVUS Announces Proposed Offering of Convertible Senior NotesGlobeNewswire(Wed, May 15)
- VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 213.36 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.44 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | -0.14 |
|---|
Business Summary
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
View More